OPTIMIZERx Corp (OPRX)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $138.26M
Last updated: Nov 17, 2026 at 11:06 AM ET
OPTIMIZERx Corp (OPRX) Earnings: Report Dates and Results
OPTIMIZERx (OPRX) is expected to report earnings on Mar 3, 2027. In the quarter ended Sep 30, 2026, OPTIMIZERx reported EPS of $0.13, above the $0.07 estimate. It beat the EPS estimate in each of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
OPRX has an expected report date of Mar 3, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 21.6% below the $0.51 reported for the quarter ended Dec 31, 2025.
OPRX Earnings Call
The latest OPRX earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 36 quarters below that had an estimate, OPRX beat 23, missed 9 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $21.61M, down 17.1% from $26.07M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.13 | $0.07 | N/A | +85.71% | Beat | -35.0% | 5 | 0 up, 1 down | Nov 11, 2026 | $21.61M |
| Jun 30, 2026 | $0.08 | $0.01 | N/A | +700.00% | Beat | -50.0% | 5 | 0 up, 1 down | Aug 12, 2026 | $20.50M |
| Mar 31, 2026 | Not reported | $0.03 | -$0.06 - $0.04 | N/A | Not reported | N/A | 6 | 1 up, 1 down | May 12, 2026 | $19.84M |
| Dec 31, 2025 | $0.51 | $0.22 | $0.19 - $0.25 | +131.82% | Beat | +264.3% | 7 | 0 up, 2 down | Mar 5, 2026 | $32.24M |
| Sep 30, 2025 | $0.20 | $0.04 | $0.00 - $0.12 | +400.00% | Beat | +66.7% | 7 | 1 up, 0 down | Nov 6, 2025 | $26.07M |
| Jun 30, 2025 | $0.16 | -$0.09 | N/A | +277.78% | Beat | +700.0% | 7 | 6 up, 1 down | Aug 7, 2025 | $29.20M |
| Mar 31, 2025 | $0.08 | -$0.12 | -$0.18 - -$0.04 | +166.67% | Beat | N/A | 7 | 0 up, 5 down | May 12, 2025 | $21.93M |
| Dec 31, 2024 | $0.14 | $0.10 | N/A | +40.00% | Beat | -46.2% | 8 | 2 up, 0 down | Mar 12, 2025 | $32.32M |
| Sep 30, 2024 | $0.12 | $0.06 | $0.01 - $0.10 | +100.00% | Beat | +33.3% | 7 | 0 up, 0 down | Nov 13, 2024 | $21.31M |
| Jun 30, 2024 | $0.02 | -$0.07 | -$0.09 - $0.00 | +128.57% | Beat | N/A | 6 | 0 up, 0 down | Aug 8, 2024 | $18.81M |
| Mar 31, 2024 | -$0.11 | -$0.10 | -$0.25 - -$0.03 | -10.00% | Miss | N/A | 6 | 2 up, 0 down | May 14, 2024 | $19.69M |
| Dec 31, 2023 | $0.26 | $0.32 | $0.23 - $0.53 | -18.75% | Miss | +4.0% | 6 | 2 up, 0 down | Mar 28, 2024 | $28.37M |
| Sep 30, 2023 | $0.09 | $0.04 | -$0.03 - $0.05 | +125.00% | Beat | +28.6% | 6 | 3 up, 0 down | Nov 6, 2023 | $16.33M |
| Jun 30, 2023 | -$0.01 | -$0.02 | -$0.04 - $0.00 | +50.00% | Beat | -125.0% | 7 | 0 up, 0 down | Aug 14, 2023 | $13.82M |
| Mar 31, 2023 | -$0.09 | -$0.08 | -$0.11 - -$0.04 | -12.50% | Miss | N/A | 7 | 0 up, 1 down | May 10, 2023 | $13.00M |
| Dec 31, 2022 | $0.25 | $0.24 | $0.20 - $0.28 | +4.17% | Beat | +13.6% | 7 | 0 up, 0 down | Mar 8, 2023 | $19.65M |
| Sep 30, 2022 | $0.07 | $0.04 | $0.01 - $0.06 | +75.00% | Beat | -22.2% | 7 | 0 up, 0 down | Nov 8, 2022 | $15.09M |
| Jun 30, 2022 | $0.04 | $0.09 | N/A | -55.56% | Miss | -60.0% | N/A | 0 up, 0 down | Aug 9, 2022 | $13.98M |
| Mar 31, 2022 | -$0.01 | -$0.01 | -$0.06 - $0.05 | 0.00% | In line | -133.3% | 5 | 0 up, 1 down | May 4, 2022 | $13.73M |
| Dec 31, 2021 | $0.22 | $0.21 | $0.17 - $0.22 | +4.76% | Beat | +37.5% | 5 | 3 up, 0 down | Feb 24, 2022 | $20.31M |
| Sep 30, 2021 | $0.09 | $0.13 | $0.12 - $0.15 | -30.77% | Miss | +50.0% | 4 | 0 up, 0 down | Nov 9, 2021 | $16.12M |
| Jun 30, 2021 | $0.10 | $0.07 | $0.06 - $0.08 | +42.86% | Beat | +400.0% | 5 | N/A | Aug 4, 2021 | $13.63M |
| Mar 31, 2021 | $0.03 | $0.01 | -$0.02 - $0.03 | +200.00% | Beat | N/A | 5 | N/A | May 6, 2021 | $11.23M |
| Dec 31, 2020 | $0.16 | $0.16 | $0.13 - $0.19 | 0.00% | In line | N/A | 4 | N/A | Feb 24, 2021 | $16.43M |
| Sep 30, 2020 | $0.06 | $0.04 | $0.03 - $0.05 | +50.00% | Beat | N/A | 4 | N/A | Nov 9, 2020 | $10.52M |
| Jun 30, 2020 | $0.02 | -$0.03 | -$0.06 - -$0.02 | +166.67% | Beat | -77.8% | 4 | N/A | Aug 5, 2020 | $8.78M |
| Mar 31, 2020 | -$0.06 | -$0.03 | -$0.07 - $0.00 | -100.00% | Miss | -200.0% | 4 | N/A | May 4, 2020 | $7.58M |
| Dec 31, 2019 | -$0.03 | $0.01 | -$0.03 - $0.03 | -400.00% | Miss | N/A | 4 | N/A | Feb 27, 2020 | $7.38M |
| Sep 30, 2019 | -$0.05 | $0.08 | $0.05 - $0.10 | -162.50% | Miss | -171.4% | 4 | N/A | Nov 5, 2019 | $5.00M |
| Jun 30, 2019 | $0.09 | $0.08 | $0.06 - $0.10 | +12.50% | Beat | +28.6% | 4 | N/A | Aug 7, 2019 | $7.01M |
| Mar 31, 2019 | $0.06 | $0.02 | N/A | +200.00% | Beat | +100.0% | 3 | N/A | May 8, 2019 | $5.21M |
| Dec 31, 2018 | -$0.01 | -$0.01 | -$0.03 - $0.00 | 0.00% | In line | N/A | 4 | N/A | Feb 26, 2019 | $6.58M |
| Sep 30, 2018 | $0.07 | $0.06 | N/A | +16.67% | Beat | N/A | 3 | N/A | Nov 5, 2018 | $5.42M |
| Jun 30, 2018 | $0.07 | $0.03 | N/A | +133.33% | Beat | N/A | 3 | N/A | Aug 7, 2018 | $5.10M |
| Mar 31, 2018 | $0.03 | -$0.03 | N/A | +200.00% | Beat | N/A | 1 | N/A | May 2, 2018 | $4.11M |
| Dec 31, 2017 | -$0.03 | -$0.03 | N/A | 0.00% | In line | N/A | N/A | N/A | Feb 27, 2018 | $2.52M |
| Sep 30, 2017 | -$0.04 | -$0.03 | N/A | -33.33% | Miss | N/A | N/A | N/A | Nov 2, 2017 | $1.40M |
| Jun 30, 2017 | -$0.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 1, 2017 | $1.26M |
| Mar 31, 2017 | -$0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 3, 2017 | $770340 |
| Dec 31, 2016 | -$0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 8, 2017 | $527330 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.95, up 458.8% from the year before. It was -$0.10 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.95 | +458.8% |
| Dec 31, 2024 | $0.17 | -32.0% |
| Dec 31, 2023 | $0.25 | -28.6% |
| Dec 31, 2022 | $0.35 | -20.5% |
| Dec 31, 2021 | $0.44 | +144.4% |
| Dec 31, 2020 | $0.18 | +157.1% |
| Dec 31, 2019 | $0.07 | -56.3% |
| Dec 31, 2018 | $0.16 | N/A |
| Dec 31, 2017 | -$0.14 | N/A |
| Dec 31, 2016 | -$0.10 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,700 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,728 | 9 | |
| 2026Q2 | Jun 30, 2026 | 5,976 | 7 | |
| 2026Q1 | Mar 31, 2026 | 4,833 | 7 | |
| 2025Q4 | Dec 31, 2025 | 6,301 | 9 | |
| 2025Q3 | Sep 30, 2025 | 5,151 | 10 | |
| 2025Q2 | Jun 30, 2025 | 4,856 | 9 | |
| 2025Q1 | Mar 31, 2025 | 5,303 | 10 | |
| 2024Q4 | Dec 31, 2024 | 6,107 | 11 |
2026Q3 Earnings Call
Opening remarks
Stephen Silvestro CEO Thank you, operator, and good afternoon, everyone. Thank you for joining our third quarter 2026 earnings call. We're pleased to report third quarter revenue of $21.6 million and adjusted EBITDA of $6.3 million, both of which exceeded consensus expectations. While revenue came in modestly ahead of expectations, our adjusted EBITDA performance was again particularly strong, reflecting our continued gross margin strength and the benefits of our disciplined approach to cost management. Importantly, our bottom line performance reflects the structural improvements we have made to our operating model, including the cost reduction initiative completed during the first half of the year. These actions have allowed us to operate more efficiently while continuing to invest in the technologies, products and commercial capabilities we believe will drive long-term growth. Although the broader pharmaceutical marketing environment remains dynamic, we believe our third quarter performance demonstrates the underlying profitability and operating leverage of our business. At the same time, we recognize that our top line performance has not yet reflected the full potential of investments we've made in our platform. Contracted revenue for 2026 continues to track approximately 20% below the comparable prior year. As a result, we have a larger amount of revenue to secure and recognize during the fourth quarter to achieve our previously issued guidance. Given this backdrop, we are updating the full year '26 revenue guidance to a range of $87 million to $93 million, while maintaining our adjusted EBITDA guidance of $21 million to $25 million. This revision reflects expected timing of our customer spending decisions and the increased amount of business that would need to convert and be recognized before year-end to achieve our previous revenue expectations. We remain encouraged by the sustainable progress we're making across our business, including a very encouraging start to 2027. We are seeing expanded opportunities within key accounts, indications of pent-up demand as customers ramp up the 2027 RFP season and growing commercial opportunities associated with our programmatic distribution capabilities. We are also pleased to report that one of our previously displaced top 5 clients has returned and begun to reinvest in new solutions with OptimizeRx. As you may recall, this customer represented a meaningful portion of our revenue in 2025, but had not generated revenue during the first 3 quarters of 2026. We are now pleased to report that we have begun generating revenue from this customer during the fourth quarter. While spending has not yet returned to historical levels, we view this as a positive development and an encouraging indication of renewed customer engagement and interest and contribution to growth next year in 2027. In addition, we're encouraged by the progress we've made by strengthening our commercial organization.
Frequently Asked Questions About OPRX
When is OPTIMIZERx's next earnings date?
OPTIMIZERx's next earnings report is expected for Mar 3, 2027.
Did OPRX beat earnings estimates last quarter?
Yes. OPTIMIZERx reported EPS of $0.13 for the quarter ended Sep 30, 2026, above the $0.07 estimate, a 85.71% surprise.
What EPS do analysts expect from OPRX next quarter?
The consensus EPS estimate for OPTIMIZERx for the quarter ending Dec 31, 2026 is $0.40 from 8 analysts, with estimates from $0.30 to $0.58.
How often does OPRX beat earnings estimates?
OPTIMIZERx beat the EPS estimate in each of the 8 most recent quarters that had an estimate, with an average surprise of +237.75%.
OPRX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors